Skip to content
10-Q

Quarterly Report

Kura Oncology, Inc. KURA

0001193125-26-219481

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 88.77M sh
Shares Diluted Q1 2026 · Mar 31, 2026 88.61M sh
Shares Diluted Q1 2026 · Mar 31, 2025 87.42M sh
Capex Q1 2026 · Mar 31, 2026 $128K
Capex Q1 2026 · Mar 31, 2025 $292K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$85.85M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$71.93M
Long Term Debt Q1 2026 · Mar 31, 2026 $9.75M
Long Term Debt Q1 2026 · Dec 31, 2025 $9.71M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $39.08M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $149.1M
Stockholders Equity Q1 2026 · Mar 31, 2026 $107.88M
Stockholders Equity Q1 2026 · Dec 31, 2025 $174.14M
Stockholders Equity Q1 2026 · Mar 31, 2025 $364.41M
Stockholders Equity Q1 2026 · Dec 31, 2024 $413.64M
Current Liabilities Q1 2026 · Mar 31, 2026 $101.5M
Current Liabilities Q1 2026 · Dec 31, 2025 $116.97M
Total Liabilities Q1 2026 · Mar 31, 2026 $544.67M
Total Liabilities Q1 2026 · Dec 31, 2025 $564.23M
Current Assets Q1 2026 · Mar 31, 2026 $623.78M
Current Assets Q1 2026 · Dec 31, 2025 $708.66M
Total Assets Q1 2026 · Mar 31, 2026 $652.55M
Total Assets Q1 2026 · Dec 31, 2025 $738.36M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.83
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.66
Eps Basic Q1 2026 · Mar 31, 2026 −$0.83
Eps Basic Q1 2026 · Mar 31, 2025 −$0.66
Sga Expense Q1 2026 · Mar 31, 2026 $31.56M
Sga Expense Q1 2026 · Mar 31, 2025 $22.84M
Rd Expense Q1 2026 · Mar 31, 2026 $65.26M
Rd Expense Q1 2026 · Mar 31, 2025 $55.97M
Net Income Q1 2026 · Mar 31, 2026 −$73.33M
Net Income Q1 2026 · Mar 31, 2025 −$57.43M
Operating Income Q1 2026 · Mar 31, 2026 −$78.82M
Operating Income Q1 2026 · Mar 31, 2025 −$64.7M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $262K
Revenue Q1 2026 · Mar 31, 2026 $18.27M
Revenue Q1 2026 · Mar 31, 2025 $14.11M